- Home
- ANL vs CLSD Comparison
ANL vs CLSD Comparison
Compare ANL & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- CLSD
- Stock Information
- Founded
- ANL 2004
- CLSD 2011
- Country
- ANL Cayman Islands
- CLSD United States
- Employees
- ANL N/A
- CLSD N/A
- Industry
- ANL
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- CLSD Health Care
- Exchange
- ANL Nasdaq
- CLSD Nasdaq
- Market Cap
- ANL 79.0M
- CLSD 74.3M
- IPO Year
- ANL 2023
- CLSD 2016
- Fundamental
- Price
- ANL $2.05
- CLSD $0.93
- Analyst Decision
- ANL Strong Buy
- CLSD Strong Buy
- Analyst Count
- ANL 2
- CLSD 6
- Target Price
- ANL $9.00
- CLSD $5.33
- AVG Volume (30 Days)
- ANL 13.8K
- CLSD 301.0K
- Earning Date
- ANL 02-24-2025
- CLSD 03-11-2025
- Dividend Yield
- ANL N/A
- CLSD N/A
- EPS Growth
- ANL N/A
- CLSD N/A
- EPS
- ANL N/A
- CLSD N/A
- Revenue
- ANL $5,000,000.00
- CLSD $7,703,000.00
- Revenue This Year
- ANL N/A
- CLSD N/A
- Revenue Next Year
- ANL N/A
- CLSD $91.87
- P/E Ratio
- ANL N/A
- CLSD N/A
- Revenue Growth
- ANL N/A
- CLSD 248.39
- 52 Week Low
- ANL $1.85
- CLSD $0.80
- 52 Week High
- ANL $17.48
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- ANL 44.92
- CLSD 42.76
- Support Level
- ANL $2.00
- CLSD $0.90
- Resistance Level
- ANL $2.19
- CLSD $0.97
- Average True Range (ATR)
- ANL 0.27
- CLSD 0.05
- MACD
- ANL -0.01
- CLSD 0.00
- Stochastic Oscillator
- ANL 16.81
- CLSD 24.29
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.